Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal MabThera in severe progressive multiple sclerosis
2008-002626-11Phase 2Completed
- Sponsor
- Department of Neurology
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in multiple sclerosis (MS), sponsored by Department of Neurology. Primary endpoint: Safety parameters during intrathecal MabThera therapy. Started Apr 2009; status: completed.
02
Drugs
rituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2008-002626-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002626-11.